Sub Categories

Search

Newsletter

BNP-26 Fluorescent EIA Kit Maximize

BNP-26 Fluorescent EIA Kit

BNP-26 Fluorescent EIA Kit (Porcine, Ovine)(FEK-011-08) is an in-vitro quantitative procedured designed to determine levels of porcine or ovine brain natriuretic peptide-26 (BNP-26).

More details

FEK-011-08

96 wells

£ 480.00

BNP-26 Fluorescent EIA Kit

Specificity : Porcine, Ovine
Sensitivity : 16.9 pg/ml
Linear Range: 16.9-668 pg/ml
Range: 0-10000 pg/ml
Size: 96 tests

Reagents Supplied:
- 96 well immunoplate (1 plate)
- 20x assay buffer concentrate (50ml)
- Standard peptide (1 vial).
- Primary antibody (rabbit anti-peptide IgG) (1 vial).
- Positive control (1 vial).
- Acetate plate sealer (APS), (3 pieces)
- Streptavidin-horseradish peroxidase (SA-HRP) (30μl)
- Substrate solution (12ml)
- Biotinylated peptide (1 vial).
- Stable peroxide solution (1.5ml)
- Stop solution (12ml)
- General protocol (1 book).
- Assay diagram (1 sheet).

Intended Use:
BNP-26 fluorescent EIA (porcine, ovine) is intended to be used for quantitatively detecting amounts of porcine and ovine brain natriuretic peptide-26 (BNP-26) in samples of plasma, CSF, serum, urine or any biological fluid.

Assay Principle:
1. The microwell plates have been pre-coated with secondary antibody and also the non-specific binding sites have been blocked.
2. Secondary antibody is able to bind with the Fc fragment of the primary antibody, the Fab segment is competitively bound by both biotinylated peptides and the peptide standard or the targeted peptide in samples.
3. Biotinylated peptide can then interact with the SA-HRP, which then catalyzes the substrate solution.
4. Fluorescence intensity is directly proportional to the amount of biotinylated peptide-SA-HRP complex but inversely proportional to the amount of the peptide in standard solutions or samples.
5. Unknown concentration in samples can then be determined by extrapolation from a standard curve.

Cross Reactivity:
BNP-26 (Porcine or Ovine) 100%.
BNP-32 (Porcine)  100%.
BNP-32 (Rat)  0%.
BNP-45 (Rat)  0
BNP-32 (Human)  0%.
Alpha ANP (1-28) (Human, Canine) 0%.

Background:
Brain natriuretic peptide (BNP-26) was first discovered in extracts of porcine brain, whereas within humans it is found to be made in the cardiac ventricles. It is a 26 a.a. polypeptide which has been found to be secreted by the ventricles of heart when there is excessive stretching of myocytes, it is also released alongside an NT-proBNP (76 amino acids amino terminal fragment). Elevated levels of BNP 26 and/or NT-proBNP within the blood are useful markers in the diagnosis of heart failure and acute congestive heart failure (CHF).

References
1. Vet J. (2008) 178 (1): 85-90. Analytical validation of commercial immunoassays for the measurement of cardiovascular peptides in the dog. Schellenberg S, et al.
2. Vet J. (2008) 178 (1): 85-90. Analytical validation of commercial immunoassays for the measurement of cardiovascular peptides in the dog. Schellenberg S, et al.
3. J Cardiovasc Pharmacol. (2008) 52 (3): 253-61. Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure. Bartha et al.
4. Circulation. (2007) 115 (1): 67-75. Hemodynamic Modulation of Endocardial Thromboresistance. Kapur et al.
5. Clin Chem. (2011) 57 (6): 864-73. Secretion of glycosylated pro-B-type natriuretic peptide from normal cardiomyocytes. Tonne JM et al.
6. J Vet Intern Med. (2008) 22 (5): 1118-23. Evaluation of NT-pro BNP and CT-ANP as markers of concentric hypertrophy in dogs with a model of compensated aortic stenosis. Hori Y, et al.

Special Offers